Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

被引：305

作者：

Charles, PGP

Ward, PB

Johnson, PDR

Howden, BP

Grayson, ML

机构：

[1] Austin Hlth, Dept Infect Dis, Heidelberg, Vic 3084, Australia

[2] Austin Hlth, Dept Microbiol, Heidelberg, Vic 3084, Australia

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 38卷 / 03期

关键词：

D O I：

10.1086/381093

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n = 53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n=5, 9.4%) with those due to vancomycin-susceptible MRSA (n = 48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P = .001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P < .001), and initially low serum vancomycin levels (P = .006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.

引用

收藏

页码：448 / 451

页数：4

相关论文

共 18 条

[1] Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin [J].

Ariza, J ;

Pujol, M ;

Cabo, J ;

Peña, C ;

Fernández, N ;

Liñares, J ;

Ayats, J ;

Gudiol, F .

LANCET, 1999, 353 (9164) :1587-1588

[2] Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001 [J].

Fridkin, SK ;

Hageman, J ;

McDougal, LK ;

Mohammed, J ;

Jarvis, WR ;

Perl, TM ;

Tenover, FC .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) :429-439

[3]

Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542

[4] Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area [J].

Geisel, R ;

Schmitz, FJ ;

Thomas, L ;

Berns, G ;

Zetsche, O ;

Ulrich, B ;

Fluit, AC ;

Labischinsky, H ;

Witte, W .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (06) :846-848

[5]

Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3

[6] Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin [J].

Hiramatsu, K ;

Aritaka, N ;

Hanaki, H ;

Kawasaki, S ;

Hosoda, Y ;

Hori, S ;

Fukuchi, Y ;

Kobayashi, I .

LANCET, 1997, 350 (9092) :1670-1673

[7] Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].

Hiramatsu, K ;

Hanaki, H ;

Ino, T ;

Yabuta, K ;

Oguri, T ;

Tenover, FC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :135-136

[8] Staphylococcus aureus with heterogeneous resistance to vancomycin:: Epidemiology, clinical significance, and critical assessment of diagnostic methods [J].

Liu, C ;

Chambers, HF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3040-3045

[9] Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus:: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains [J].

Murchan, S ;

Kaufmann, ME ;

Deplano, A ;

de Ryck, R ;

Struelens, M ;

Zinn, CE ;

Fussing, V ;

Salmenlinna, S ;

Vuopio-Varkila, J ;

El Solh, N ;

Cuny, C ;

Witte, W ;

Tassios, PT ;

Legakis, N ;

van Leeuwen, W ;

van Belkum, A ;

Vindel, A ;

Laconcha, I ;

Garaizar, J ;

Haeggman, S ;

Olsson-Liljequist, B ;

Ransjo, U ;

Coombes, G ;

Cookson, B .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (04) :1574-1585

[10]

Standards NCfCL, 2000, M7A5 NCCLS